Jaguar8 commented on a stock · Jun 4, 2024 19:13

NEWS

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire exclusive rights to Cortibon. This collaboration aims to advance precision medicine in treating MDD, potentially addressing up to 50% of MDD patients worldwide. The collaboration leverages genetic markers to predict medication response, aiming to enhance treatment efficacy and reduce costs.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

7923 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6636

Followers

Following

71K

Visitors